v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
REVENUES:        
Product revenue $ 10,240,650 $ 7,186,795 $ 28,156,571 $ 17,204,909
License revenue 35,708 35,708 107,125 107,125
Total Revenues 10,276,358 7,222,503 28,263,696 17,312,034
OPERATING EXPENSES:        
Cost of product revenue (exclusive of amortization expense shown below) 11,855,464 7,916,220 42,180,319 27,812,635
Research and development 1,708,391 491,404 4,893,549 1,879,025
Plasma center operating expenses 1,218,898 456,899 2,597,444 1,705,498
Amortization of intangible assets 178,838 211,235 536,514 633,704
Selling, general and administrative 9,115,744 7,197,173 25,750,458 18,878,690
Total operating expenses 24,077,335 16,272,931 75,958,284 50,909,552
LOSS FROM OPERATIONS (13,800,977) (9,050,428) (47,694,588) (33,597,518)
OTHER INCOME (EXPENSE):        
Interest and other income 1,164 281,896 268,643 619,103
Interest expense (3,091,200) (2,649,404) (8,875,597) (6,262,489)
Loss on extinguishment of debt 0 0 0 (9,962,495)
Gain on transfer of plasma center assets 0 0 0 11,527,421
Other expense, net (26,440) (20,523) (39,232) (42,308)
Other income expense, net (3,116,476) (2,388,031) (8,646,186) (4,120,768)
NET LOSS $ (16,917,453) $ (11,438,459) $ (56,340,774) $ (37,718,286)
BASIC AND DILUTED LOSS PER COMMON SHARE $ (0.19) $ (0.19) $ (0.68) $ (0.72)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:        
Basic and Diluted 87,698,258 59,317,830 82,627,753 52,673,190

Source